PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Juder the Paperwork Reduction Act of 1995, no persons are required to respond to

TRADEM INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a valid OMB control number.				
Application Number	09/891,602			
Filing Date	June 26, 2001			
First Named Inventor	Dyatkin			
Group Art Unit	1625			
Examiner Name	C. Aulakh			
Attorney Docket Number	ORT-1451			

				U.S. PATENT DOCUMENTS		
		U.S. Patent Document				
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
				·		RECEIVE
						JUL 3 1 200
						TECH CENTER 1600
						
			FOREIC	ON PATENT DOCUMENTS		

		Foreign	Patent Docume	ent	T TOO ON LINE			
Examiner Initials	Cite No.1	Office ³		indCode ⁵	Name of,Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T⁰
CA		wo	00/43354	A2	Elan Pharmaceuticals, Inc.	07/27/2000		
CA		wo	99/06436	A1	Athena Neurosciences Inc.	02/11/1999		
CA		wo	99/06433	A1	Athena Neurosciences Inc.	02/11/1990		F
CA		wo	98/53814	A1	Merck & Co., Inc.	12/03/1998		
CA		wo	98/53817	A1	Merck & Co., Inc.	12/03/1998		
CA		EP	0947506	A1	Pfizer Products Inc.	10/06/1999		
						1.		

Examiner		
Signature AislAr V	Date	A 11 A
*EXAMINER: Initial if reference associated in the	Considered	9-4-62
*EXAMINER: Initial if reference considered, whether or not citation is in conforman and not considered. Include copy of this form with next communication to applicant	ice with MPEP 609. Draw lin	e through citation if not in confo
and not considered. Include copy of this form with next communication to applicant	t.	o amough diadon in flot in conformance

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. a Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	09/891,602
Filing Date	June 26, 2001
First Named Inventor	Dyatkin
Group Art Unit	1625
Examiner Name	C. Aulakh
Attorney Docket Number	ORT-1451

			 				01(1-1401		j.
	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	<u> </u>	. Patent Do		(ind Code ²	Pages, Colu where relevant relevant figu	Dassages or	
				<u> </u>	<u> </u>			ECEN	fl .
								JL 3 1 7	l i
			<u>- </u>				TECH C	ENTER 10	00/290(
							·		
	T	FOREIG	V PATENT	DOCUME	NTS				
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document		atent Docum		where rele	olumns, Lines, evant passages vant figures	T6	
	1,10.			7	Milucode"	a	ppear	`	

Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	where relevant pass or relevant figure			Pages, Columns, Lines, where relevant passages or relevant figures	T6
ļ ———	110.		011100	Number	KindCode ⁵	appear	'
 -	+		Ĺ_	1	1		
				 			1 •
	 			 			
	 -						
	1			 			
		-		 	_		
	<u> </u>				_		
	T -	OTHER PRIOR ART - NO	N PATENT	LITERATU	RE DOCUMEN	TS	
Examiner 's Initials*	Cite No. ¹	Include name of the author (in CA title of the item (book, magazine, volume-issue number(s)					T²
CA		PCT Search Report for PCT/US 01/2085	7 dated Mar	rh 18 2002			
			- Jacob Wali	GI 10, 2002			
		<u> </u>					

Examiner	<u> </u>		
ignature		ate	1 . (0
3	TUCKI a	onsidered 4 4 L	1602

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to 449A/PTO

MENTORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for for

(use as many sheets as necessary) Sheet 2 of 2

a valid OMB control number.
09/891,602
June 26, 2001
Dyatkin
1625
C. Aulakh
ORT-1451

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	I		
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²		
Initials*	No.1 publisher, city and/or country where published				
CA	<u> </u>	Osborn, L.; et al., Cell, 1989, 59, 1203	11/		
CP_	L	Wayner, E. A.; et al., Cell Biol., 1989, 109, 1321	IVE		
CA	<u> </u>	Bayless, K. J.; et al., J. Cell Sci., 1998, 111, 1165			
CA	<u> </u>	Adams, S. P.; et al., Ann. Rep. Med. Chem., 1999, 34, 179	200		
CA	<u> </u>	Chuluyan, H. E.; et al., Springer Semin. Immunopathol., 1995, 16, 391	200,		
LCA_	!	Simmons, P. J.; et al., Blood, 1992, 80, 388	<u></u>		
CA_	<u> </u>	Shroff, H. N.; et al., Bioorg. Med. Chem. Lett., 1998, 8, 1601	R 1600		
CA CA	ļ	105111Rawa, 11., et al., 5. Hillinghol., 1550, 100,	1 1000		
	<u> </u>	Laberge, S.; et al., Am. J. Respir. Crit. Care Med., 1995, 151, 822	ļ		
CA.	ļ	Barbadillo, C.; et al., Springer Semin. Immunopathol., 1995, 16, 375			
CA_	ļ	Powrie, F.; et al., Ther. Immunol., 1995, 2, 115			
GA_	!	Tamraz, S.; et al., Springer Semin. Immunopathol. 1995, 16, 437			
CA	ļ	Molossi, S.; et al., J. Clin. Invest. 1995, 95, 2601			
CA	ļ	Lin, K-C.; et al., J. Med. Chem. 1999, 42, 920	<u> </u>		
CA	i	Kling D, Fingerle J, Harlan JM, Lobb, RR and Lang, F, Mononuclear leukocytes invade rabbit arterial intima	1		
CA	1	during thickening formation via CD-18 and VLA-4-dependent mechanisms and stimulate smooth muscle	<u> </u>		
	 	migration, Circ. Res., 1995, 77, 1121-1128 Lumsden AB, Chen C, Hughes JD, Kelly AB, Hanson S and Harker L, Anti-VLA-4 antibody reduces intimal			
CA]	hyperplasia in the endarterectomized carotid artery in non-human primates, J. Vasc. Surg., 1997, 26, 87-93			
<u> </u>	 	Labinez M, Hoffert C, pels K, Aggarawal S, Pepinsky RB, Leonw D, Koteliansky V, Lobb, RR and O'Brien	 		
CA	1	EO, Infusion on and anti-alpha4 integrin antibody is associated with less adventitial formation after balloon	l		
	1	injury of porcine coronary arteries, Can. J. Cardiol., 2000, 16, 187-196			
CA	1	O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K,	 		
CH	1	Benjamin CD, et al., Vascular cell adhesion molecule-1 is expressed in human atherosclerotic plaques:			
		implications for the mode of progression of advanced atherosclerosis, J. Clin .Invest., 1993, 92, 945-951			
CA	,	Nakahima Y, Raines EW, Plump AS, Breslow JL and Ross R, Upregulation of VCAM-1 and ICAM-1 at			
Ch		atherosclerotic-prone sites on the endothelium of ApoE-deficient mouse, Arterioscler. Thromb. Vasc. Biol.,			
		1998, 18, 842-851			
		Ilyama K, Hajra L, Ilyam M, Li,H, DiChura M, Medoff BD and Cybulsky MI, Patterns of vascular cell			
CA	1	adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic			
	<u></u>	lesion and at sites predisposed to lesion formation, Circ. Res., 1999, 85, 199-207			
CA		Shih PT, Brennan M-L, Vora DK, Territo MC, Strahl D, Elices MJ, Aldons J and Berliner JA, Blocking very	į		
C14		late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet,			
	ļ	Circ. Res., 1999, 84, 345-351			
CA		Huo Y, Hafez-Moghadem A and Ley K, Role of vascular cell adhesion molecule-1 and fibronectin	1		
		connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions, Circ. Res., 2000,			
	 	87, 153-159	 		
CA	 	Hamann, A.; et al., J. Immunol. 1994, 152, 3282			
- 		Hanninen, A.C.; et al., J. Clin. Invest. 1993, 92, 2509 Fong, S.; et al., Immunol. Res. 1997, 16, 299			
CA	├	Yang, X.; et al., Diabetes 1997, 46, 1542	 		
8A	 	Tang, X., et al., Diabetes 1997, 46, 1942 Gould, Philip L., Ref. International J. Pharm., 1986, 33, 201-217			
CA	 				
1 !_H	<u>L</u>	Berge et al., J. Pharm.Sci., 1997 (Jan), 66, 1, 1	<u> </u>		

		· · · · · · · · · · · · · · · · · · ·	
Examiner Signature	AULAKY	Date Considered	9-4-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.